CVC  AbbVie Biotech Ventures

     Office Locations:

1 Waukegan Road North
Chicago, IL 60064
Phone: 847-938-9400



  • Early
  • Seed



  • Life Sciences & Healthcare
  • Medical Device



    AbbVie Biotech Ventures, Inc. (ABVI) is a subsidiary of AbbVie dedicated to making venture capital investments in emerging biotech and pharmaceutical companies. Unlike traditional venture capital firms, ABVI characterizes an investment's success by its potential to significantly increase AbbVie's strategic growth, and not solely by its financial return. Companies with programs ranging from pre-clinical (18 months prior to first-in-human) to early proof-of-concept are of highest interest for potential investment by ABVI. ABVI invests in technologies that are strategic to AbbVie such as neuroscience, immunology, virology, and oncology, as well as emerging or more opportunistic areas of innovation that have the potential to complement AbbVie's existing portfolio or to expand AbbVie's future business reach. The initial investment can range from several hundred thousand dollars up to several million, depending on the opportunity and development stage. However, ABVI will always remain a minority investor.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Charles Kunsch PhD Director
    David Donabedian Ph.D. Managing Director
    Dieter Ziegler PhD Director
    John Gustofson Senior Director
    Margarita I. Chavez Director


    Recent Funding Events (trailing 12 months):







      Rheostat Therapeutics



      Series A





      Series A


      Magnolia Neurosciences



      Series A


      Carisma Therapeutics



      Series A


      Quentis Therapeutics



      Series A


    Portfolio companies include:


    Recent News: